Tullio Palmerini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2340075/publications.pdf

Version: 2024-02-01

		567281	888059
18	2,872 citations	15	17
papers	citations	h-index	g-index
10	10	10	2511
18	18	18	3511
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, The, 2012, 379, 1393-1402.	13.7	854
2	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet, The, 2015, 385, 2371-2382.	13.7	345
3	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1845-1854.	2.8	343
4	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology, 2016, 68, 1851-1864.	2.8	319
5	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
6	Clinical Outcomes With Bioabsorbable Polymer-Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. Journal of the American College of Cardiology, 2014, 63, 299-307.	2.8	269
7	Stent Thrombosis With Drug-Eluting Stents. Journal of the American College of Cardiology, 2013, 62, 1915-1921.	2.8	119
8	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2111-2118.	2.8	85
9	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. International Journal of Cardiology, 2018, 268, 61-67.	1.7	46
10	Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. Journal of the American College of Cardiology, 2004, 44, 1570-1577.	2.8	42
11	Predictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation: Cardiovascular Interventions, 2011, 4, 577-584.	3.9	38
12	Impact of Gene Polymorphisms, PlateletÂReactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in PatientsÂWithÂNon–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	2.9	38
13	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention, 2016, 12, 312-318.	3.2	27
14	Target Lesion Failure With Current Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 2868-2878.	2.9	22
15	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. International Journal of Cardiology, 2018, 259, 20-25.	1.7	18
16	In vitro thrombogenicity of drug-eluting and bare metal stents. Thrombosis Research, 2020, 185, 43-48.	1.7	5
17	The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial. Journal of Invasive Cardiology, 2015, 27, 203-11.	0.4	5
18	Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?. International Journal of Cardiology, 2018, 271, 30.	1.7	0